



**MULTI-REGIONAL
CLINICAL TRIALS**

THE MRCT CENTER OF
BRIGHAM AND WOMEN'S HOSPITAL
and HARVARD

The Clinical Research Glossary Biannual Meeting

Adoption, Implementation, and Impact

building community around health literacy

Welcome!

LOCATION:

Virtual

DATE:


June 16, 2026

TIME:

12-1:30 pm EST



Welcome





Disclaimer

The views and findings expressed today are ours, serving in our individual capacity, and do not imply endorsement or reflect the views or policies of Mass General Brigham, Harvard Medical School, or any affiliated organization or entity.

The MRCT Center is supported by voluntary contributions from foundations, corporations, international organizations, academic institutions, and government entities (see www.MRCTCenter.org) as well as by grants.

We are committed to autonomy in our research and to transparency in our relationships. The MRCT Center—and its directors—retain responsibility and final control of the content of any products, results and deliverables.



Webinar Logistics




- **This webinar is being recorded.**
 - The recording, slides and other resources will be made available on the MRCT Center website within the next week.
- **Please use the Q&A to ask questions.**
 - We will do our best to respond live – but will provide written responses to the questions we were unable to answer.
- **Please introduce yourself in the chat.**
 - We'd love to hear where you're joining from and why you decided to join this webinar today.



Overview of Today's Session



- 1) Introduction to the MRCT Center and the Clinical Research Glossary
- 2) Industry and Patient Partner Perspectives
- 3) Panel Discussion and Audience Questions
- 4) Closing



About the MRCT Center



Our Vision

Improve the integrity, safety, and rigor of clinical trials around the world.

Our Community

We engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.

www.mrctcenter.org



CLINICAL TRIALS & RESEARCH 

- Cell and Gene Therapies
- Artificial Intelligence (AI) and Clinical Research
- Environmental Sustainability in Clinical Trials
- From Policy to Practice: Implementing the EHDS for Responsible
- [Data Sharing](#)
- [Health Literacy in Clinical Research](#)
- Informed Consent, Reimagined
- Oversight and Implementation of Decentralized Elements in Clinical Trials
- Post-Trial Responsibilities
- Promoting Global Clinical Research in Children
- Protocol Ethics Toolkit and E-Learning
- Real World Evidence
- Representation in Research
- Return of Aggregate Results
- Return of Individual Results

FOR PATIENTS & PARTICIPANTS 

QUALITY & TRANSPARENCY 

- Advancing the Quality of Clinical Trial Enterprise
- Data Sharing
- Impact of Privacy Laws on Clinical Research
- Policy Engagement
- Proactive Safety Surveillance: A Global Approach

CAPACITY BUILDING 

- Global Regulatory Engagement
- Joint Task Force for Clinical Trial Competency
- Research Ethics Committee Systems Optimization
- Training & Education

CLINICAL RESEARCH GLOSSARY 

BIOETHICS COLLABORATIVE 

**RESEARCH, DEVELOPMENT, & REGULATORY
ROUNDTABLE (R3)** 

PROJECT-SPECIFIC WEBSITES

- [Health Literacy in Clinical Research](#)
- Joint Task Force for Clinical Trial Competency
- Return of Individual Results

SEE ALL OUR WORK 

[Accessibility
Menu](#)



Ongoing Commitment to Health Literacy



2017 - Release of Return of Results toolkits and guidance that incorporated health literacy principles

2019 - Completed a multi-stakeholder initiative focused on health literacy and launched a publicly available website on Health Literacy in Clinical Research.

www.mrctcenter.org/health-literacy

2020 - Developed COVID-19 pamphlets to support understanding of clinical research (in English & Spanish).

<https://mrctcenter.org/blog/resources/covid-19-clinical-research-flyers/>

2020 to 2021 - Piloted and launched the first version of the Clinical Research Glossary! <https://mrctcenter.org/glossary/>

2025 - Developed and released a set of [data literacy infographics](#).

2026 - health literacy in clinical research, patient engagement, and return of results updates!

Ongoing: glossary development, maintenance, and dissemination

The image shows a screenshot of the 'HEALTH LITERACY IN CLINICAL RESEARCH' website. The website header includes 'HEALTH LITERACY IN CLINICAL RESEARCH' and navigation links: 'START HERE', 'TRIAL LIFE CYCLE', 'BEST PRACTICES', and 'RESOURCES BY ROLE'. Below the header, there is a section titled 'I AM HEALTHY: Should I Join a COVID-19 Research Study?' with a sub-header 'People who do not have COVID-19 can help researchers learn more.' The infographic on the right, titled 'What Happens to Data During a Research Study?', is divided into five sections: 'Collect Data', 'Code Data', 'Save Data', 'Clean Data', and 'Analyze Data'. Each section includes a list of bullet points explaining the process. At the bottom of the infographic, there is a section titled 'You have the right to ask questions about your data.' with a list of questions. The infographic also features logos for 'MULTI-REGIONAL CLINICAL TRIALS' and 'phuse'.

HEALTH LITERACY IN CLINICAL RESEARCH

START HERE | TRIAL LIFE CYCLE | BEST PRACTICES | RESOURCES BY ROLE

I AM HEALTHY: Should I Join a COVID-19 Research Study?

People who do not have COVID-19 can help researchers learn more.

A research study:

- collects new information
- tries to answer new questions
- needs volunteers to sign up

COVID-19:

- is a new disease caused by coronavirus.
- may cause some people to have weakness, muscle and other symptoms.
- can be mild, but it can also lead to death.

What should I ask the researcher?

- ✓ Why is the study being done?
- ✓ What will happen if I join?
- ✓ Could the study help me?
- ✓ Could the study cause any harm?
- ✓ Do I have to pay money?
- ✓ Will I be paid to be in the study?

What else is being done?

What Happens to Data During a Research Study?

Collect Data

- There are many ways to collect data.
- For example, data is collected when you complete a survey, participate in an interview, have a lab test, or record measurements like height, weight, and blood pressure.

Code Data

- You are assigned a code, a series of numbers and letters that identify your data.
- A code is created so direct personal identifiers like your name and contact information are kept separate from your research data.
- Data is coded to protect your identity.

Save Data

- Coded data is saved in a database.
- The database contains data from all study participants.
- The database is kept safe and secure with protection methods such as passwords.

Clean Data

- Data is checked and cleaned by the study team to make sure all information is correct.
- Data is monitored by outside groups for participant safety and research integrity.

Analyze Data

- Data from all the participants is combined.
- The combined data is analyzed by the research teams as they work to answer the study's research questions.

You have the right to ask questions about your data.

- What data will be collected in this study?
- Who will have access to my data?
- How will my data be protected?
- How can my data help answer the research question?
- How can I find out the results of the study?
- For how long will my data be kept?

MULTI-REGIONAL CLINICAL TRIALS
THE MRCT CENTER OF BRIGHAM AND WOMEN'S HOSPITAL, HARVARD

phuse

Learn more about what happens to your data: mrctcenter.org/resource/data-infographics/



Helping you understand clinical research

The **Clinical Research** Glossary offers easy to understand clinical research definitions.

All definitions are developed by the MRCT Center and a committed team of patient advocates and other professionals in medicine and research. Before definitions are released, they are reviewed by members of the public.

The Clinical Research Glossary started as a pilot project in 2020 and is now a CDISC global standard for clear communication. This means that more and more groups are learning about and using this resource.

Welcome! We hope this resource is helpful to you.

- LEARN MORE
- GET INVOLVED
- MEET THE TEAM
- DOWNLOAD ▾



Search glossary

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

additive effect -

The combined effect when two or more things are used together.

adherence -

Following the study directions and requirements.

adverse event -

Any health problem that happens during the study.

<https://mrctcenter.org/glossary/>

Thank you to the current team!



Development Team

Rebecca Baker, *CDISC*
Lisa Chamberlain James, *Trilogy Writing*
Sudipta Chakraborty, *Biogen*
R Bernard Coley, *Advocate*
Deborah Collyar, *PAIR/Advocate*
Scott Finger, *CISCRP*
Rick Galli, *CIHR Centre for REACH*
Kavita Garg, *Saliegral*
Helle Gawrylewski, *Hawkwood Consulting, LLC*
Art Gertel, *MedSciCom, LLC*
Julia Hild, *Boehringer-Ingelheim*
Maureen Kashuba, *Merck & Co.*


Rena Lubker, *Medical University of South Carolina*
Josh Mailman, *Advocate*
Erin Muhlbradt, *CDISC/NCI EVS*
Pavithra Mukunda, *Stanford*
Marilyn Neault (co-lead), Advocate
Harold Silverman, *Argenx*
Gloria Stone, *G Stone Connections*
Cornelia Weiss-Haljiti, *Boehringer-Ingelheim*
Peery White, *Strengthening Native Connections LLC*

Review Team

Roberta Albany, *Advocate*
Jessica Chaikof, *Advocate*
Maura Cummings, *Advocate*
Joseph Haddad, *Advocate*
Crystal Hendricks-Kretzer, *Advocate*
Sheila Polite, *Advocate*
TJ Sharpe, *Advocate*
Desiree Walker (co-lead), Advocate

Expert Advisory Committee


Behtash Bahador *CISCRP* Elizabeth Brown *Merck* Jay Duhig *AbbVie* Malgorzata Sztolsztener *Astra Zeneca* Marian Ryan *Institute for Healthcare Advancement* Nathalie Bohm *Pfizer* Robert Weker *Advocate*



Clinical Research Glossary Collaboration Highlights



- Long-standing, diverse, multi-interest-holder team
- Monthly meetings for verbal feedback and discussion about content
- Opportunities for written feedback submission and one-on-one meetings to share comments
- Concurrent image development process with information designer
- Ongoing, active collaboration with the Clinical Data Interchange Standards Consortium (CDISC)
- Public Review every June
- Updated Clinical Research Glossary released every September



A step in the overall [clinical research](#) process to test a new drug or treatment.

“ Example of *phase* in a sentence

Research is done in *phases* to make sure a study treatment is safe and then whether it works before it is approved.

More Info

A phase is a step in the research process. Phases of research studies build on each other and each phase has a separate goal.

Phase 1 studies are usually the first to [enroll](#) humans and test for safety.

Phase 2 studies test if the drug, or treatment works.


Phase 3 studies compare the study treatment to the usual, standard treatment.

Phase 4 studies continue to collect data after a study treatment is approved. These are sometimes called post-marketing studies.

Other info to think about when joining a study

You may see the term “phase” when you are reading about [clinical trials](#).

Before you [enroll](#) in a [clinical trial](#) you may want to ask about what phase the study is in. You may also want to know more about the information the study team already has about the risks and benefits of the study treatment that is being tested.



[Download image](#)

[Accessibility Menu](#)

Related Words

[clinical research](#)

[clinical trial](#)

[preclinical study](#)



Other Resources

[NCI Thesaurus](#)

[FDA - The Drug Development Process, Step 3: Clinical Research](#)



If you know of other resources we should link to to help explain this word, please [contact us](#).

phase

cdisc

A step in the overall [clinical research](#) process to test a new drug or treatment.

“ Example of *phase* in a sentence

Research is done in *phases* to make sure a study treatment is safe and then whether it works before it is approved.

More Info

A phase is a step in the research process. Phases of research studies build on each other and each phase has a separate goal.

Phase 1 studies are usually the first to [enroll](#) humans and test for safety.

Phase 2 studies test if the drug, or treatment works.


Phase 3 studies compare the study treatment to the usual, standard treatment.

Phase 4 studies continue to collect data after a study treatment is approved. These are sometimes called post-marketing studies.

Other info to think about when joining a study

You may see the term “phase” when you are reading about [clinical trials](#).

Before you [enroll](#) in a [clinical trial](#) you may want to ask about what phase the study is in. You may also want to know more about the information the study team already has about the risks and benefits of the study treatment that is being tested.



[Download image](#)

Accessibility
Menu

↔ Related Words

[clinical research](#)

[clinical trial](#)

[preclinical study](#)



Other Resources

[NCI Thesaurus](#)

[FDA - The Drug Development Process, Step 3: Clinical Research](#)



If you know of other resources we should link to to help explain this word, please [contact us](#).


The MRCT Center Collaboration with CDISC



- Develops and advances data standards of the highest quality to transform incompatible formats, inconsistent methodologies, and diverse perspectives into a robust framework for generating accessible clinical research data.
- Convenes a global community of research experts representing a range of experiences and backgrounds to harness the collective power to drive more meaningful clinical research.
- Offers public review periods for new additions to its standards, when feedback can be collected from its users.

The plain language definitions developed by the MRCT Center Clinical Research Glossary Workgroup started being included in the CDISC standards in 2023.

<https://www.cdisc.org/>



A step in the overall [clinical research](#) process to test a new drug or treatment.

“ Example of *phase* in a sentence

Research is done in *phases* to make sure a study treatment is safe and then whether it works before it is approved.

i More Info

A phase is a step in the research process. Phases of research studies build on each other and each phase has a separate goal.

Phase 1 studies are usually the first to [enroll](#) humans and test for safety.

Phase 2 studies test if the drug, or treatment works.


Phase 3 studies compare the study treatment to the usual, standard treatment.

Phase 4 studies continue to collect data after a study treatment is approved. These are sometimes called post-marketing studies.

Other info to think about when joining a study

You may see the term “phase” when you are reading about [clinical trials](#).

Before you [enroll](#) in a [clinical trial](#) you may want to ask about what phase the study is in. You may also want to know more about the information the study team already has about the risks and benefits of the study treatment that is being tested.



[Download image](#)

Accessibility Menu

↔ Related Words

[clinical research](#)


[clinical trial](#)

[preclinical study](#)

🔗 Other Resources

[NCI Thesaurus](#)

[FDA - The Drug Development Process, Step 3: Clinical Research](#)

 If you know of other resources we should link to to help explain this word, please [contact us](#).

The EVS website hosts biomedical terminologies that NCI does not own or control. Some of these sources may contain gender-related terminology that does not comply with Executive Order 14168

Trial Phase (Code - C48281) --
[Open in Hierarchy](#)
[Term Suggestion Form](#)
[Collapse All](#)
[Export](#)
[New Search](#)
[All](#) | [caDSR](#) | [CDISC](#) | [CDISC-GLOSS](#) | [ICH](#) | [MRCT-Ctr](#) | [NCI](#) | [PCDC](#)

NCI Thesaurus Code:	C48281 (Search for linked caDSR metadata)
Semantic Type(s):	Classification
Preferred Name:	Trial Phase

[Synonyms](#)
[Other Properties](#)
[Parent/Child Concepts](#)
[Roles and Associations](#)
Definitions (5) [\[top\]](#)

Definition ↑↓	Source ↑↓	Attribution
A stage in the clinical research and development of a therapy from first-in-human to post-approval clinical trials.	ICH	
A stage in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998] See also Phase 0-5, epoch (if reference is to a single trial), phase (within a study), clinical research and development.	CDISC-GLOSS	
A step in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]	CDISC	
A step in the overall clinical research process to test a new drug or treatment. (https://mrctcenter.org/glossaryterm/phase/)	MRCT-Ctr	
Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.	NCI	from PDtrials.org Glossary

<https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48281>


2026 Clinical Research Glossary Public Review with CDISC

June 12th through July 13th

Twenty-seven (27) definitions up for review:

- o24 new terms
- o3 updated terms

Access the feedback survey here:




"Can I accept this definition?"



These definitions are meant to be in plain language for the general public.

These definitions do not have to be "perfect" but rather should be simple definitions that can help people who are learning more about clinical research.

- Consider: **"Is the change I am requesting really necessary? Can I accept the definition as written?"**
- Keep definitions as a single sentence.
- Avoid long, complex sentences with several pieces of information or commas within one sentence.
- Do not use brackets to separate ideas, or symbols, or abbreviations such as "e.g." and "i.e."
- Use short, simple words that don't have more than one meaning or connotation
- Use a tone that is more like how you might speak to someone.
- Be precise and concise while leaving out unnecessary words
- Use active voice when possible






Media Kit

Clinical Research Glossary Public Review

3RD EDITION: JUNE 2026



Health
Literacy



https://mrcrcenter.org/wp-content/uploads/2026/06/2026-06_Glossary_Public-Review_Media-Kit.pdf

MRCT Center Clinical Research Glossary Social Media Post Suggestions

There are a few options to support sharing of the public review period via social media:

1) Write your own posts!

For example, tell your network you are excited to invite them to be part of the public review process. You can use the glossary to enhance your post. [credit-the-mrct-center-when-using-the-glossary](#)

2) Share MRCT Center posts on social media

You can follow us on LinkedIn to get updates on our network, or just search for us, and share our posts. <https://www.linkedin.com/company/multi-regional-clinical-trials-center-of-brigham-and-women's-hospital-and-harvard>

3) Use our template language on social media

Plain language is for everyone! The MRCT Center has new Clinical Research Glossary (CRG) definitions that will be reviewed in this June 2026 CDISC Public Review.

Access the survey here: <https://redcap.partners.org/redcap/surveys/?s=CJ7TL4YM8MEDAR1>

Before publication and release of the definitions, we will be open for comments. Anyone interested in providing feedback is a great way to have your voice heard and bring up points that may not have been considered when creating the definitions.

Access the survey here: <https://redcap.partners.org/redcap/surveys/?s=CJ7TL4YM8MEDAR1>

3 Media Kit for Public Review

MRCT Center Clinical Research Glossary Public Review Email/Newsletter Template

Use this email/newsletter template to inform your community of practice via email or regularly scheduled newsletter.

Subject/Title

MRCT Center Clinical Research Glossary Annual Public Review Process of New Definitions: June 12th through July 13th, 2026.

Body

<Insert Organization Name here> is thrilled to announce that The MRCT Center's Clinical Research Glossary (CRG) is ready for the public to review new terms and definitions. This June 2026 CDISC Public Review will include words to be released in September.

What is Public Review?

Before publication and release, all terms and their definitions are put out to the public for comments to ensure different voices are heard. The MRCT Center team and the group of volunteers from across the clinical research ecosystem strive to produce meaningful plain language definitions. Hearing from the public and integrating new feedback is essential to this work. Transparency is a major priority of this effort.

How To Get Involved

Anyone interested in providing comments is free to do so! This is a great way to have your voice heard and bring up points that may not have been considered when creating the definitions.


Click here to fill out the Public Review survey:

<https://redcap.partners.org/redcap/surveys/?s=CJ7TL4YM8MEDAR1>

4 Media Kit for Public Review



Glossary Analytics - Jan 1 to May 31, 2026




Country

- United States
- India
- United Kingdom
- Canada
- Australia
- France

Language


- Spanish; Castilian
- English
- French
- Dutch; Flemish
- German
- Arabic



>2,200 users
83 PDF Downloads
47 Excel Downloads

Adoption, Implementation...

... and Impact



Pfizer Glossary Use Case



Glossary Use Case - Bristol Myers Squibb



Glossary Case Use - Honor Health



Glossary Case Use - CureMito




Glossary Case Use - JSCDM




Glossary MGB Rally PDF



Glossary Case Use - TriCan Health




Biogen Glossary Use Case



Glossary Case Use - Special Interest - Black Diaspora

Your case could be here!
Help us grow our library and build our community.
Share your use cases!



<https://mrctcenter.org/glossary/clinical-research-glossary-use-case-collection/>



Meet the Speakers



Moderated by:



Anna Subrizi

Senior Director, Patient Empowerment, Bristol Myers Squibb



Sudipta Chakraborty, PhD

Head, Health Literacy & Plain Language Center of Excellence, Biogen



R Bernard Coley

Co-Chair, Special Interest Group - Black Diaspora Care Partner, Research Advocate

2026 World Parkinson Coalition Robin A. Elliott Community Service Award



Sylvia Baedorf Kassis

Program Director, MRCT Center



Meet the Speakers



Anna Subrizi

Senior Director, Patient
Empowerment, Bristol
Myers Squibb

Corporate Affairs


Global Purpose & Patient Experience



Patient Empowerment
Anna Subrizi

UNIVERSAL PATIENT LANGUAGE® and the UPL Logo are trademarks of Bristol-Myers Squibb Company.

Vision: To shape a future where every patient and caregiver interaction is clear, empathetic, and trusted — where people feel heard, understood, and leave confident in what comes next





MISSION:

At Bristol Myers Squibb (BMS), our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are committed to advancing research, improving lives, and making information clear and accessible. Through our Universal Patient Language® (UPL) program, we simplify complex medical terms and promote health literacy so patients and caregivers can make informed decisions. We also work to expand access to treatment and advocate for health equity.

POPULATION SERVED:

Teams across BMS leverage the Multi-Regional Clinical Trials (MRCT) Clinical Research Glossary when creating materials for patients, caregivers, and the general public. Examples include plain language summaries, informed consent forms, and branded or unbranded patient educational materials.

USE OF THE GLOSSARY:

The Clinical Research Glossary is included in our suite of Universal Patient Language® (UPL) tools as a source of patient-friendly definitions on the UPL website, www.UPL.org. Additionally, it is referenced in our internal UPL Glossary, which is used across BMS when creating public-facing materials.

EXTERNAL RESOURCES

- Need help with accessibility? [Web Content Accessibility Guidelines \(WCAG\)](#)
- Need plain language? Check out a few glossaries to help:
 - [Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard Clinical Research Glossary](#)
 - [Centers for Disease Control \(CDC\) Plain Language Thesaurus](#)
 - [US Center for Disease Control and Prevention National Cancer Institute Dictionary of Cancer Terms](#)

FAQs

How do I use these tools?

Learn how to apply these resources in your work from planning content to creating patient-friendly communication.



Building Assets

Building Assets are ready-to-use visual tools designed to help teams communicate medical concepts more clearly and consistently. These assets can be dropped directly into patient materials to support understanding, reinforce key messages, and align content with UPL standards.

When you download this package, you'll receive the **Graphic Assets Library**, which includes a foundational set of illustrations and visual elements created specifically to enhance patient-friendly communication.

[Download Graphic Assets Library](#)



Assessment Tools

Assessment Tools support teams in evaluating how well their communications reflect the UPL principles and truly serve patient needs. They can be used at any stage of development to guide improvements, spark reflection, and measure real-world impact.

When you download these tools, you'll receive two resources: the **Reflection Guide**, which helps teams self-assess clarity, empathy, and alignment with the UPL, and the **Patient Impact Measurement Framework**, which offers hypotheses and research questions to understand how UPL-aligned materials influence patient experience.

[Download All Assessment Tools](#)

Disclaimer: Bristol Myers Squibb (BMS) is not responsible for third-party content on this website. We do not review or verify materials posted by other users, and their views do not represent Bristol Myers Squibb.

Challenges – Opportunities for Growth



SHIFTING LANGUAGE TAKES TIME

- Moving teams away from familiar scientific or regulatory terminology requires patience and sustained effort
- Building comfort with simpler, clearer alternatives to deeply ingrained technical language is an ongoing process

LEARNING NEW WAYS TO SOCIALIZE

- Adapting IT systems and finding effective ways to share the Clinical Research Glossary across a large enterprise
- These were viewed as opportunities rather than barriers – each step forward strengthened adoption and team buy-in

THE REFRAME

- No true barriers – each challenge was an opportunity to grow and strengthen the program
- Cross-communication between R&D and Commercial teams opened doors to new collaborations and broader glossary adoption
- The Clinical Research Glossary itself became a bridge – a trusted, science-backed resource that helped teams align around consistent plain language
- When patients don't understand the language, they can't fully engage – this principle kept the team motivated through every adjustment



What Comes Next

SCALING HEALTH LITERACY

- Embedding health literacy principles and tools more systematically into enterprise-wide processes
- Continuing to evaluate new and innovative ways to drive organizational and individual health literacy
- Continuing to leverage and share the Clinical Research Glossary as a reliable source of information for teams and patients alike

TECHNOLOGY & INNOVATION


- Exploring how technology – including AI – can support and accelerate plain language adoption

PARTNERING WITH PATIENTS

- Working more closely with patients to co-create language that truly works for them
- Driving consistent, uniform plain language definitions across the healthcare system to empower patients in their care

SHARING BROADLY

- Continuing to offer UPL as a free resource on UPL.org and sharing the glossary to meet patients where they are in their journey
- Actively recommending the Clinical Research Glossary in trainings and conversations as a go-to source for meaningful plain language terms





Meet the Speakers



Sudipta Chakraborty, PhD

Head, Health Literacy &
Plain Language Center of
Excellence, Biogen

Biogen - Center of Excellence under R&D




Research & Development

Global Clinical Operations

Clinical Trial Accelerator Unit

Clinical Trial Transparency



Health Literacy & Plain Language
Center of Excellence
Sudipta Chakraborty



Centralized resource spreading the health literacy gospel



- ★ Arose out of a **growing need** for non-promotional, inclusive, and plain-language friendly content beyond those required for transparency regulations
- ★ Specialized and dedicated support for producing **plain language-friendly content** that will create efficiencies and ensure consistent messaging to patients and the public
- ★ A dedicated unit to support **cross-functional needs**
- ★ Opportunities for **additional collaborations** beyond R&D
- ★ A **training/educational resource** on health literacy principles and plain language best practices based on SME domain knowledge and industry standards





MISSION:

Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities.

We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

POPULATION SERVED:


Internal use for functions creating patient- and public-facing materials (currently transparency, informed consent, and patient engagement)

USE OF THE GLOSSARY:

- The MRCT glossary was one of several sources used to develop Biogen's initial Plain Language Glossary in 2022. It became the exclusive reference for Version 2.0, released in April 2025.
- At the heart of a content reuse initiative, the MRCT glossary supports efforts to build tools and refine processes that drive efficiency and ensure clear, consistent content across teams.
- **Our ultimate goal is to enhance patient centricity throughout the organization by delivering consistent, readable messaging to study participants and the public at every stage of drug development.**



Creating a cross-functional plain language glossary



Collaboration between the ICM, PCE, and CTT functions at Biogen



Referenced **established glossaries** in addition to internal ones:

- University of Michigan Plain Language Medical Dictionary
- EMA Medical Terms Simplifier
- **MRCT Clinical Research Glossary**



Initial version launched in **2022**



Version 2.0 launched in 2025; featuring updates solely based on internal feedback + **MRCT alignment**

Ongoing and Future Initiatives





Meet the Speakers



R Bernard Coley

Co-Chair, Special Interest
Group - Black Diaspora
Care Partner, Research
Advocate

2026 World Parkinson
Coalition Robin A. Elliott
Community Service Award


Glossary use case - Special Interest Group - Black Diaspora



I am a member of the MRCT Center Clinical Research Glossary development team.



- Experienced firsthand the meticulous detail and in-depth effort that goes into the development of definitions, additional information, where used examples, and graphics to assist literacy that go into each clinical research term in the glossary.
- Proceeded with confidence to use this plain language glossary in my community service work in educating under-engaged health community members.




Glossary use case - The Black Parkinson's Disease Summit



Annually, I produce many of the educational sessions designed to reach this under-engaged community impacted by Parkinson's Disease to increase participation in clinical research.



- Dedicated one entire day to providing an educational overview of clinical research and especially the clinical trials process and protocols.
- Utilized the Clinical Research Glossary to guide the plain language communications of descriptions of participant encountered aspects of clinical trials, e.g., informed consent contents.
- Onboarded our audience to essential terminology and an intelligible reference source.
- Feedback and reviews were outstanding.




Glossary use case - Challenges and the Future



The MRCT Center Clinical Research Glossary is a work in progress.




- Challenge: Not every term or category of needed terms were released in the public version of the glossary at the time of our summit session.
- Challenge: Participants had to be left on their own for additional exploration with personally encountered terms found in patient materials.
- Challenge: Spent time explaining that plain language does not imply reduced accuracy or a dumbed down glossary product.
- Future: Based on the responses, we will repeat the summit session utilizing the MRCT Center Clinical Research Glossary again.





Panel Discussion and Questions



Closing





THINK + DO

THANK YOU!